InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 2 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Results 1 - 20 of 32 : 1 2 Next »

Recs

0
Member Avatar damoninak (94.33) Submitted: 2/26/2014 1:40:28 AM : Outperform Start Price: $35.83 ITMN Score: +97.30

It's awesome

Recs

0
Member Avatar tad40 (99.61) Submitted: 2/25/2014 3:19:39 PM : Underperform Start Price: $37.17 ITMN Score: -89.58

TOO MUCH, TOO QUICK

Recs

1
Member Avatar SkepBioInvestor (96.45) Submitted: 2/9/2014 1:30:59 PM : Outperform Start Price: $12.44 ITMN Score: +481.75

Positive ASCEND data

Recs

1
Member Avatar HIGHG33K (89.96) Submitted: 2/4/2014 12:21:59 AM : Outperform Start Price: $12.16 ITMN Score: +492.38

great value

Recs

0
Member Avatar SnarkyApple (50.20) Submitted: 9/17/2012 4:08:56 PM : Outperform Start Price: $9.69 ITMN Score: +624.88

Shenanigans.

Recs

0
Member Avatar SorrySam (74.77) Submitted: 4/21/2012 2:54:57 AM : Outperform Start Price: $12.12 ITMN Score: +461.96

qvt financial who made blockbuster calls on mdvn, inhx, etc.

Recs

0
Member Avatar EclecticRecluse (79.86) Submitted: 3/23/2011 7:41:55 AM : Underperform Start Price: $43.86 ITMN Score: -12.06

Low Sales and Few Employees for Capital

Recs

0
Member Avatar bg019818 (34.23) Submitted: 12/31/2010 9:18:42 AM : Outperform Start Price: $36.78 ITMN Score: +40.25

Breakthrough in its lung disease drug.

Recs

0
Member Avatar diansacc (< 20) Submitted: 12/27/2010 5:14:57 PM : Underperform Start Price: $38.01 ITMN Score: -34.22

itmn

Recs

0
Member Avatar flipsmurf (86.82) Submitted: 6/14/2010 5:04:23 PM : Outperform Start Price: $9.75 ITMN Score: +574.98

Great new product and way oversold at current price

Recs

0
Member Avatar aldebaranccs (26.73) Submitted: 6/11/2010 3:49:56 PM : Outperform Start Price: $9.53 ITMN Score: +591.40

bull

Recs

0
Member Avatar jkok (67.31) Submitted: 5/6/2010 9:54:29 AM : Outperform Start Price: $13.01 ITMN Score: +395.27

recently suffered

Recs

1
Member Avatar BlackshearFund (< 20) Submitted: 5/5/2010 7:30:47 PM : Outperform Start Price: $10.06 ITMN Score: +561.48

Oversold. Might see 15's again soon.

Recs

0
Member Avatar Zolton7620 (< 20) Submitted: 3/23/2010 3:28:50 AM : Outperform Start Price: $40.95 ITMN Score: +7.73

The drug pirfenidone now under consideration by the FDA for approval for treatment of Idiopathic Pulmonary Function is also effective for MS and a number of other diseases yet to be fully tested.

Recs

0
Member Avatar Biotech2010 (51.49) Submitted: 1/26/2010 8:56:24 PM : Underperform Start Price: $14.13 ITMN Score: -338.21

13.47

Recs

0
Member Avatar bvdbreaker (< 20) Submitted: 10/8/2009 7:42:32 AM : Outperform Start Price: $14.06 ITMN Score: +336.27

undervalued pipeline, period

Recs

0
Member Avatar pmtrain (89.17) Submitted: 2/10/2009 5:26:34 AM : Outperform Start Price: $18.62 ITMN Score: +158.98

hpc trials are taking this company higher almost daily feb 2009 (best owned performer)

Recs

0
Member Avatar apsunick (96.68) Submitted: 2/9/2009 5:00:43 PM : Outperform Start Price: $18.62 ITMN Score: +158.98

With CAPACITY ready to roll and FDA announcement in about 10 months, the high short interest should continue to push the shares higher as short sellers begin to exit.

Recs

0
Member Avatar pick1998 (81.58) Submitted: 2/3/2009 10:38:44 AM : Underperform Start Price: $15.10 ITMN Score: -242.21

Mixed data on PFD (pirfenidone) for IPF (idiopathic pulmonary fibrosis) make the regulatory path uncertain. FDA usually don't accept exploratory data analysis. Its HCV program yields good data, but may lose to the crowded competitors. Higher debt than cash is another warning sign. I expect to drop under 10.

Recs

0
Member Avatar StevenJL (< 20) Submitted: 2/3/2009 9:52:57 AM : Outperform Start Price: $15.11 ITMN Score: +241.11

Strong results of trial

CEO looking at all possibilities to bring drug to market

Drug companies are losing revenue with drugs coming off patent so will be eager to buy new drugs

Results 1 - 20 of 32 : 1 2 Next »

Featured Broker Partners


Advertisement